Innovative MedTech Inc.
Other OTCTotal Valuation
Innovative MedTech Inc. carries a market capitalization of 89,758.00, placing it among publicly traded companies globally. Its enterprise value stands at 3.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 89,758.00 |
| Enterprise Value | 3.05M |
Share Statistics
Innovative MedTech Inc. currently has 59.84M shares outstanding.
| Shares Outstanding | 59.84M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Innovative MedTech Inc. trades at a trailing price-to-earnings ratio of 1.90. The price-to-sales ratio is 5.63, and the price-to-book ratio stands at -0.06.
| PE Ratio | 1.90 |
| PS Ratio | 5.63 |
| PB Ratio | -0.06 |
| P/TBV Ratio | -2.29 |
| P/FCF Ratio | 0.84 |
| P/OCF Ratio | 0.84 |
Enterprise Valuation
| EV / Sales | 7.11 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 1.00 |
Financial Position
Innovative MedTech Inc. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -61.65, indicating conservative leverage, while an interest coverage ratio of -15.68 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.02 |
| Quick Ratio | 0.02 |
| Debt / Equity | -61.65 |
| Debt / EBITDA | -0.25 |
| Interest Coverage | -15.68 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 281.26 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Innovative MedTech Inc.'s stock has declined approximately -98.10654% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | -98.10654% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.04 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Innovative MedTech Inc. generated 428,384.00 in revenue and converted that into 1.27M in net income, yielding earnings per share of -0.06. EBITDA reached -2.64M, while operating income came in at -2.66M.
| Revenue | 428,384.00 |
| Gross Profit | N/A |
| Operating Income | -2.66M |
| Pretax Income | -2.13M |
| Net Income | 1.27M |
| EBITDA | -2.64M |
| EBIT | -2.66M |
| Earnings Per Share (EPS) | -0.06 |
Balance Sheet
Innovative MedTech Inc. holds 13,616.00 in cash and equivalents against 649,205.00 in total debt, resulting in a net debt position of 635,589.00. Total book value stands at -43.29M, with working capital of -1.28M providing operational flexibility.
| Cash & Cash Equivalents | 13,616.00 |
| Total Debt | 649,205.00 |
| Net Debt | 635,589.00 |
| Equity (Book Value) | -43.29M |
| Book Value Per Share | -1.17 |
| Working Capital | -1.28M |
Cash Flow
Innovative MedTech Inc. produced 2.85M in operating cash flow over the past twelve months. After subtracting -11,555.00 in capital expenditures, free cash flow totaled 2.84M - equivalent to 0.08 per share.
| Operating Cash Flow | 2.85M |
| Capital Expenditures | -11,555.00 |
| Free Cash Flow | 2.84M |
| FCF Per Share | 0.08 |
Margins
Innovative MedTech Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -620.52 and net profit margin of 296.21 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -620.52 |
| Pretax Margin | -497.44 |
| Profit Margin | 296.21 |
| EBITDA Margin | -617.40 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -14.64 |
| FCF Yield | 118.84 |
Stock Splits
Innovative MedTech Inc.'s most recent stock split took place on March 9, 2021 with a 10000:1 split ratio.
| Last Split Date | 3/9/2021 |
| Split Ratio | 10000:1 |
Scores
Innovative MedTech Inc. posts an Altman Z-Score of -280.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -280.39 |